Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Luma Meds vs Maves

Luma Meds
Graded #391

Lower grade

vs+14
Maves
Graded #89

Higher grade

The verdict

Maves takes it — 71.8/100 to 57.8/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +52
32
84
Dose & formulationMaves +1
64
65
Clinical oversightLuma Meds +14
90
76
Labs & monitoringLuma Meds +3
55
52
FulfillmentMaves +11
76
87
Contract termsMaves +35
20
55
Luma Meds · left barMaves · right bar

The numbers

MetricLuma MedsMaves
WeighScore57.8/10071.8/100
GradeCC
Scorecard rank#391#89
Semaglutide$249/mo (compounded)$99/mo (starting dose, first-month rate, compounded)
Tirzepatide$299/mo (compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Luma Meds

Graded #391 · C

Strengths

  • LegitScript certified — a credibility mark fewer compounded GLP-1 providers carry
  • Free discreet shipping and unlimited 24/7 support on every plan
  • Compounded semaglutide and tirzepatide from FDA-regulated 503A/503B pharmacies
  • '100,000+ members treated' claim with physician-supervised online care
  • 3-month bundle pricing brings semaglutide as low as $140/mo

Where it loses points

  • Compounding pharmacy partner not publicly named
  • States available not published
  • Monthly semaglutide ($249/mo) is above many lower-cost compounded competitors
  • No oral formulation options listed
  • Compounded medications are not FDA-approved
Maves

Graded #89 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard